Chemotherapy, Stem Cell Transplant, and Romidepsin in Treating Patients with T-cell Non-Hodgkin Lymphoma

Inclusion Criteria

• CR or PR required; remission status will be assessed at the completion of induction chemotherapy and prior to enrollment on protocol
• The following histologies will need to be confirmed at Memorial Sloan-Kettering Cancer Center (MSK) or locally for participating sites in order to be considered for HDT-ASCT and post-transplant maintenance romidepsin: * Peripheral T-cell lymphoma (PTCL) * Angioimmunoblastic T-cell lymphoma (AITL) * Anaplastic large-cell lymphoma (ALCL) * Enteropathy-associated T-cell lymphoma (EaTCL) * Hepatosplenic gamma delta T-cell lymphoma * Adult T-cell leukemia/lymphoma * Primary cutaneous gamma/delta T-cell lymphoma * Extranodal natural killer (NK)/T-cell lymphoma, nasal type * Primary cutaneous anaplastic large cell lymphoma * Subcutaneous panniculitis-like T-cell lymphoma * Mycosis fungoides/Sezary syndrome
• A minimum of 2 x 10^6 cluster of differentiation 34 positive (CD34+) cells must have been collected
• Total bilirubin =< 1.5 x upper limit of normal (ULN)
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN

Exclusion Criteria

• Progressive disease at transplant work-up
• Prior autologous or allogeneic transplant
• Active and uncontrolled infection at time of transplantation including active infection with Aspergillus or other mold, or human immunodeficiency virus (HIV) infection
• Inadequate performance status/organ function defined by diffusing capacity of the lung for carbon monoxide (DLCO) < 50% (adjusted for hemoglobin [hgb]), cardiac function as defined below, Karnofsky performance status (KPS) < 60%
• Pregnant or breast-feeding; for males and females of child-producing potential, inability to use effective contraceptive methods during the study
• Prior therapy with romidepsin
• Central nervous system or meningeal involvement
• Any known cardiac abnormalities such as: * Congenital long QT syndrome * Corrected QT (QTc) interval >= 500 milliseconds * Myocardial infarction within 6 months of transplantation; subjects with a history of myocardial infarction between 6 and 12 months prior to transplant who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate * Other significant electrocardiogram (ECG) abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min) * Symptomatic coronary artery disease (CAD), e.g., angina Canadian class II-IV; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present * An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of >= 2 mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present * Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction < 40% by multi gated acquisition (MUGA) scan or < 50% by echocardiogram and/or magnetic resonance imaging (MRI) * A known history or sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsade de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD) * Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes * Uncontrolled hypertension, defined as blood pressure (BP) >= 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria * Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers) * Patients taking drugs leading to significant QT prolongation within the specified wash out period * Concomitant use of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors
• Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up and research tests